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Abstract
Using a series of known inhibitors of the bacterial NorA efflux pump and the
pharmacophore generation program CATALYST® the first predictive pharmacophore
for inhibitors of this pump has been developed. The pharmacophore consists of 3
hydrophobic features, a ring aromatic feature, 16 excluded volumes and one hydrogen
bond acceptor. This pharmacophore was subsequently used to search the NCI database
for new compound leads and also for de novo design. Two 1,4-naphthoquinones and an
aromatic azo compound were identified as possible leads from the NCI database of
compounds. These compounds were tested for NorA efflux inhibition in Staphylococcus
aureus and they showed inhibitory activity. The de novo design process identified a
number of new biaryl ether and biaryl ketone target compounds as potential inhibitors.
A biaryl ether target 2-[3-(3-methoxyphenoxy)phenyl]isoindoline-1,3-dione, was
synthesised by a concise three step process. This compound showed moderate NorA
pump inhibitory activity in Staphylococcus aureus, using berberine as the antibacterial
pump substrate. Thus this biaryl ether could serve as the starting point for a new class of
inhibitors.
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